Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Common Equity (2022 - 2025)

Historic Common Equity for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $219.0 million.

  • Taysha Gene Therapies' Common Equity rose 14661.76% to $219.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.0 million, marking a year-over-year increase of 14661.76%. This contributed to the annual value of $71.5 million for FY2024, which is 455.32% down from last year.
  • Taysha Gene Therapies' Common Equity amounted to $219.0 million in Q3 2025, which was up 14661.76% from $248.7 million recorded in Q2 2025.
  • Taysha Gene Therapies' Common Equity's 5-year high stood at $248.7 million during Q2 2025, with a 5-year trough of -$49.1 million in Q3 2023.
  • For the 4-year period, Taysha Gene Therapies' Common Equity averaged around $61.0 million, with its median value being $53.8 million (2024).
  • Examining YoY changes over the last 5 years, Taysha Gene Therapies' Common Equity showed a top increase of 779641.73% in 2023 and a maximum decrease of 55888.07% in 2023.
  • Taysha Gene Therapies' Common Equity (Quarter) stood at $949000.0 in 2022, then surged by 7796.42% to $74.9 million in 2023, then fell by 4.55% to $71.5 million in 2024, then skyrocketed by 206.17% to $219.0 million in 2025.
  • Its Common Equity stands at $219.0 million for Q3 2025, versus $248.7 million for Q2 2025 and $55.1 million for Q1 2025.